Sanofi SA and Isis Pharmaceutical Inc drug, Kynamro has been suggested by a panel of US Food and Drug Administration, which comprised of even outside experts.

The drug has been introduced as a treatment for an unusual genetic condition, which leads to high levels of cholesterol and the sufferers, ultimately struggle with severe heart diseases.

Out of the nine members in panel, six were in favor of recommending the drug for homozygous familial hypercholesterolemia, or HoFH. The FDA advisory committee asserted that the producers have provided with reports including research based evidences, which suggest that patients assisted with 200 milligram injection will be safe as well as be able to attain the effectiveness of the drug.

The drug has been claimed to beneficial for one in 1 million Americans diagnosed of HoFH. Moreover, the company has been reported to have already started with clinical trials on a cholesterol treatment, which even include medication for lowering lipids.

Further, it has been detailed that despite being aware of the side-effects of the drug, which include liver problems and significant risk of developing cancer, the panel has recommended the drug.

The FDA regulators will now be deciding the fate of the drug and would be giving the final decision regarding the generically known mipomersen sodium by end of January.